Drugs / Labetuzumab Govitecan
Labetuzumab Govitecan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01270698 | May 2011 → Dec 2014 | colorectal cancer | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01605318 | Feb 2013 → Jan 2017 | rectal cancer | Gilead Sciences | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01915472 | Sep 2013 → Aug 2015 | colorectal cancer | Gilead Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Labetuzumab Govitecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01605318 ↗ |
| Known as | Anti-ceacam5-sn 38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544923 ↗ |
| Known as | IMMU 130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01915472 ↗ |
| Action | Inhibit | “DNA topoisomerase 1 inhibitor” CHEMBL3544923 ↗ |
| Route | Intravenous | “IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.” NCT01270698 ↗ |
| Target | CEACAM5 | “Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent” CHEMBL3544923 ↗ |
| Target | TOP1 | “DNA topoisomerase 1 inhibitor” CHEMBL3544923 ↗ |